Disease · MONDO_0005052
Comparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 50
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Linaclotide (CC) vs Linaclotide (IBS-C): Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | 399 of 523 | 748 of 1,032 | 1,555 | NCT00765999 | Trial comparisons |
| Linaclotide (CC) vs Linaclotide (IBS-C): serious adverse events | 31 of 523 | 57 of 1,032 | 1,555 | NCT00765999 | Trial comparisons |
| LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): deaths from any cause | 1 of 508 | 0 of 318 | 826 | NCT02590432 | Trial comparisons |
| LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): serious adverse events | 16 of 508 | 6 of 318 | 826 | NCT02590432 | Trial comparisons |
| LINZESS® 145 μg (CIC, Open Label) vs LINZESS® 290 μg (IBS-C, Open Label): Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum | 3 of 498 | 1 of 309 | 807 | NCT02590432 | Trial comparisons |
| Linaclotide vs Placebo: serious adverse events | 4 of 402 | 7 of 403 | 805 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Abdominal Pain Responder, 9 Out of 12 Weeks | 156 of 401 | 79 of 403 | 804 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks | 135 of 401 | 56 of 403 | 804 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks | 51 of 401 | 12 of 403 | 804 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Abdominal Pain Responder for 6 Out of 12 Weeks | 196 of 401 | 139 of 403 | 804 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment | 191 of 401 | 91 of 403 | 804 | NCT00938717 | Trial comparisons |
| Linaclotide vs Placebo: Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks | 72 of 401 | 20 of 403 | 804 | NCT00938717 | Trial comparisons |
| Rifaximin vs Placebo: serious adverse events | 7 of 315 | 7 of 320 | 635 | NCT00724126 | Trial comparisons |
| Lubiprostone Study Period I vs Placebo Study Period I: serious adverse events | 5 of 396 | 2 of 192 | 588 | NCT00380250 | Trial comparisons |
| Ibodutant 10 mg vs Placebo: serious adverse events | 0 of 271 | 2 of 264 | 535 | NCT02107196 | Trial comparisons |
| Eluxadoline vs Placebo: deaths from any cause | 0 of 171 | 0 of 173 | 344 | NCT02959983 | Trial comparisons |
| Eluxadoline vs Placebo: serious adverse events | 1 of 171 | 3 of 173 | 344 | NCT02959983 | Trial comparisons |
| Vibegron 75 mg vs Placebo: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 37 of 111 | 37 of 111 | 222 | NCT03806127 | Trial comparisons |
| Vibegron 75 mg vs Placebo: Number of Participants With Clinically Relevant Changes From Baseline in Vital Sign Values at Week 12 | 0 of 111 | 0 of 111 | 222 | NCT03806127 | Trial comparisons |
| Vibegron 75 mg vs Placebo: Number of Participants With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values at Week 12 | 0 of 111 | 0 of 111 | 222 | NCT03806127 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005052/comparisons